Cost effective short term G-CSF treatment in 2-weekly CHOP regimens for patients with aggressive NHL.

被引：0
|
作者：
Mantovani, L
Liebmann, A
Engel, C
Lehmann, T
Niederwieser, D
Loeffler, M
机构：
[1] Inst Med Stat & Epidemiol, Leipzig, Germany
[2] Clin 2 Internal Med, Leipzig, Germany
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3752
引用
收藏
页码：178B / 178B
页数：1
相关论文
共 50 条
  • [11] G-CSF prophylaxis and neutropenic events in NHL patients receiving standard CHOP or R-CHOP -: results from a retrospective study in the UK
    Marcus, R.
    Patel, H.
    Wrigley, M.
    Breddy, J.
    Biswas, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 349 - 349
  • [12] Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas:: results of the NHL-B2 trial of the DSHNHL
    Pfreundschuh, M
    Trümper, L
    Kloess, M
    Schmits, R
    Feller, AC
    Rübe, C
    Rudolph, C
    Reiser, M
    Hossfeld, DK
    Eimermacher, H
    Hasenclever, D
    Schmitz, N
    Loeffler, M
    BLOOD, 2004, 104 (03) : 634 - 641
  • [13] GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) ALLOWS THE DELIVERY OF EFFECTIVE DOSES OF CHOP AND CVP REGIMENS IN NON-HODGKIN LYMPHOMAS
    SILVESTRI, F
    VELISIG, M
    FANIN, R
    VIRGOLINI, L
    ZAJA, F
    BARILLARI, G
    BACCARANI, M
    LEUKEMIA & LYMPHOMA, 1995, 16 (5-6) : 465 - 470
  • [14] The effect of G-CSF after CHOP chemotherapy in patients with human immunodeficiency virus (HIV) infection with non-Hodgkin's lymphomas (NHL)
    Navarro, JT
    Ribera, JM
    Gomez, J
    Vaquero, M
    Romeu, J
    Calvo, R
    Orts, M
    Flores, A
    Junca, J
    Milla, F
    Feliu, E
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 362 - 362
  • [15] A randomised study comparing 3-weekly epirubicin, cyclophosphamide and continuous infusion 5-FU (ECF) to a 2-weekly schedule with G-CSF in advanced breast cancer
    De Boer, RH
    Eisen, TG
    Ellis, PA
    Johnston, SRD
    Walsh, G
    Smith, IE
    BRITISH JOURNAL OF CANCER, 1998, 78 : 15 - 15
  • [16] Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support
    Campbell, C
    Sawka, C
    Franssen, E
    Berinstein, NL
    LEUKEMIA & LYMPHOMA, 1999, 35 (1-2) : 119 - 127
  • [17] Phase III trial of 2-weekly CHOP with rituximab for aggressive B-cell Non-Hodgkin's lymphoma in elderly patients.
    Sonneveld, Pieter
    van Putten, Wim
    Biesma, Douwe
    Holte, Harald
    van Marwijk Kooij, Marinus
    Kramer, Mark Henri H.
    Wijermans, P. W.
    Steijaert, Monique
    van Imhoff, Gustaaf W.
    Lugtenburg, P. J.
    Huijgens, P. C.
    Eriksson, Mikael
    BLOOD, 2006, 108 (11) : 66A - 66A
  • [18] 2-weekly vs. 3-weekly CHOP with and without etoposide in young patients with low-risk (low LDH) aggressive non-Hodgkin's lymphoma: Results of the completed NHL-B-1 trial of the DSHNHL.
    Pfreundschuh, M
    Truemper, L
    Schmits, R
    Kloess, M
    Schmitz, N
    Glass, B
    Rudolph, C
    Engert, A
    Mezger, D
    Hossfeld, D
    Loeffler, M
    BLOOD, 2002, 100 (11) : 92A - 92A
  • [19] Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma
    Zeynalova, S.
    Ziepert, M.
    Scholz, M.
    Schirm, S.
    Zwick, C.
    Pfreundschuh, M.
    Loeffler, M.
    ANNALS OF HEMATOLOGY, 2013, 92 (12) : 1641 - 1652
  • [20] Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma
    S. Zeynalova
    M. Ziepert
    M. Scholz
    S. Schirm
    C. Zwick
    M. Pfreundschuh
    M. Loeffler
    Annals of Hematology, 2013, 92 : 1641 - 1652
12345